{
    "nctId": "NCT00014222",
    "briefTitle": "Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer",
    "officialTitle": "A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2104,
    "primaryOutcomeMeasure": "Disease Free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast that is potentially curable\n\n  * T0-4 (dermal involvement on pathology assessment only), N0-2, M0\n  * No clinical T4 disease\n* Previously treated with one of the following:\n\n  * Total mastectomy and level II axillary node dissection\n  * Partial mastectomy and level II axillary node dissection with planned breast radiotherapy after completion of adjuvant chemotherapy regimen\\*\n  * Patients with a positive sentinel node biopsy must undergo level II axillary node dissection or sufficient nodal sampling\n  * If microscopic residual in situ or invasive disease is present at total or partial mastectomy margins, planned radiotherapy must also include a boost to the tumor bed\n* No residual tumor in the axilla after dissection\n* Axillary node positive\n\n  * Negative nodes allowed if the tumor is \u2265 1 cm and 1 or more of the following criteria defining high-risk node-negative disease are met:\n\n    * Histological grade III or,\n    * Estrogen receptor negative or,\n    * Lymphatic/vascular invasion\n* Hormone receptor status:\n\n  * Estrogen receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 60 and under\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Pre- or postmenopausal\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 5 years\n\nHematopoietic:\n\n* WBC \u2265 3,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n\nRenal:\n\n* Creatinine \u2264 1.5 times ULN\n\nCardiovascular:\n\n* LVEF \u2265 limit of normal by MUGA or echocardiogram\n* No arrhythmia requiring ongoing treatment\n* No congestive heart failure\n* No documented coronary artery disease\n\nOther:\n\n* No other malignancy except:\n\n  * Adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n  * Ductal or lobular carcinoma in situ that has been curatively treated by surgery alone\n  * Other prior malignancies (except breast cancer) curatively treated more than 5 years prior to study entry\n* No serious underlying medical illness or psychiatric or addictive disorder that would preclude study compliance\n* No known hypersensitivity to E. coli-derived products, mammalian-cell derived products, or any study agents\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No prior immunotherapy for breast cancer\n* No concurrent pegfilgrastim or darbepoetin alfa (Arm II)\n\n  * Allowed on arms 1 and 3 if medically necessary\n\nChemotherapy:\n\n* No prior chemotherapy for breast cancer\n\nEndocrine therapy:\n\n* No prior hormonal therapy for breast cancer\n* No concurrent hormone replacement therapy\n* No concurrent selective estrogen-receptor modulators (e.g., raloxifene for the treatment or prevention of osteoporosis)\n* No concurrent oral contraceptives (i.e., birth control pills)\n* No other concurrent aromatase inhibitors\n\nRadiotherapy:\n\n* See Disease Characteristics\n* No prior radiotherapy for breast cancer\n\nSurgery:\n\n* See Disease Characteristics\n* No more than 12 weeks since prior total or partial mastectomy (including re-excision of margins)\n\nOther:\n\n* At least 30 days since prior investigational drugs\n* No other concurrent investigational drugs\n* Concurrent bisphosphonates for the treatment or prevention of osteoporosis allowed",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT"
}